Company
Abiomed, Inc.
Headquarters: Danvers, MA, United States
Founded: 1981
Employees: 1,725
CEO: Mr. Michael R. Minogue
Market Cap
$17.18 Billion
USD as of Dec. 1, 2022
Abiomed, Inc. Categories
United States Healthcare Medical DevicesUnited States Healthcare United States Medical Devices
Top Competitors by Market Capitalization
Industry: Medical Devices
| Company | Market Cap (USD) |
|---|---|
| Abbott | $178.02 B |
| Stryker Corporation | $126.48 B |
| Boston Scientific Corporation | $112.32 B |
| Medtronic | $98.95 B |
| Edwards Lifesciences Corporation | $55.63 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Abiomed, Inc. has the following listings and related stock indices.
Stock: NASDAQ: ABMD wb_incandescent
Stock: BMV: ABMD wb_incandescent
Stock: Bovespa: A1BM34 wb_incandescent
Stock: FSX: AIO wb_incandescent
Product & Services
Cardiovascular medical implant devices
Key People
Michael R. Minogue, CEO Thorston Siess, CTO Chuck Simonton, CMO Dr. David M. Weber, COO Andrew Greenfield, CCO
Financials
Revenue: US$840.88 million (2020)
Operating income: US$249.22 million (2020)
Net income: US$203.01 million (2020)
Total assets: US$1.2 billion (2020)
Total equity: US$1.06 billion (2020)